Evidence map›Paper›PMID 36563127›Full record

ArticleAnnals of clinical and translational neurology2023

Preliminary validity of the Draw a Shape Test for upper extremity assessment in multiple sclerosis.

Jennifer S Graves, Marco Ganzetti, Frank Dondelinger, Florian Lipsmeier, Shibeshih Belachew, Corrado Bernasconi, Xavier Montalban, Johan van Beek, Michael Baker, Christian Gossens and 1 more

Abstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Sensors in Multiple Sclerosis.Current neurology and neuroscience reports · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jennifer S GravesDepartment of Neurosciences, University of California San Diego, San Diego, California, USA.ORCID 0000-0003-1539-1940
Marco GanzettiF. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID 0000-0002-7049-171X
Frank DondelingerF. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID 0000-0003-1816-6300
Florian LipsmeierF. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID 0000-0002-8663-819X
Shibeshih BelachewF. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID 0000-0003-3976-1950
Corrado BernasconiF. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID 0000-0002-1019-5468
Xavier MontalbanDepartment of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0002-0098-9918
Johan van BeekF. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID 0000-0002-5641-0004
Michael BakerF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Christian GossensF. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID 0000-0003-2660-5895
Michael LindemannF. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID 0000-0003-1010-3890

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo validate the smartphone sensor-based Draw a Shape Test - a part of the Floodlight Proof-of-Concept app for remotely assessing multiple sclerosis-related upper extremity impairment by tracing six different shapes.

methodsPeople with multiple sclerosis, classified functionally normal/abnormal via their Nine-Hole Peg Test time, and healthy controls participated in a 24-week, nonrandomized study. Spatial (trace accuracy), temporal (mean and variability in linear, angular, and radial drawing velocities, and dwell time ratio), and spatiotemporal features (trace celerity) were cross-sectionally analyzed for correlation with standard clinical and brain magnetic resonance imaging (normalized brain volume and total lesion volume) disease burden measures, and for capacity to differentiate people with multiple sclerosis from healthy controls.

resultsData from 69 people with multiple sclerosis and 18 healthy controls were analyzed. Trace accuracy (all shapes), linear velocity variability (circle, figure-of-8, spiral shapes), and radial velocity variability (spiral shape) had a mostly fair/moderate-to-good correlation (|r| = 0.14-0.66) with all disease burden measures. Trace celerity also had mostly fair/moderate-to-good correlation (|r| = 0.18-0.41) with Nine-Hole Peg Test performance, cerebellar functional system score, and brain magnetic resonance imaging. Furthermore, partial correlation analysis related these results to motor impairment. People with multiple sclerosis showed greater drawing velocity variability, though slower mean velocity, than healthy controls. Linear velocity (spiral shape) and angular velocity (circle shape) potentially differentiate functionally normal people with multiple sclerosis from healthy controls.

interpretationThe Draw a Shape Test objectively assesses upper extremity impairment and correlates with all disease burden measures, thus aiding multiple sclerosis-related upper extremity impairment characterization.

Indexed as

Multiple SclerosisBrainHumansMagnetic Resonance ImagingSmartphoneUpper Extremity

Identifiers

PMID36563127
PMCPMC9930424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.